The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRAX | +689.81% | -55.31% | -14.88% | -29% |
| S&P | +21.6% | +71.83% | +11.43% | +94% |
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$28.00K | -100.4% |
| Gross Margin | 99.37% | 0.0% |
| Market Cap | $7.37B | 413.9% |
| Market Cap / Employee | $43.87M | 0.0% |
| Employees | 168 | 44.8% |
| Net Income | -$88,911.00K | -51.5% |
| EBITDA | -$97,016.00K | -51.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $357.33M | 65.9% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $110.00K | -91.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.68% | 21.3% |
| Return On Invested Capital | -114.78% | 9.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$77,258.00K | -35.6% |
| Operating Free Cash Flow | -$77,258.00K | -35.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.65 | 1.95 | 2.76 | 18.16 | 407.72% |
| Price to Sales | 179.78 | 98.18 | 116.29 | 156.08 | -76.95% |
| Price to Tangible Book Value | 1.65 | 1.95 | 2.76 | 18.16 | 407.72% |
| Enterprise Value to EBITDA | -6.30 | -7.93 | -11.46 | -71.01 | 295.85% |
| Return on Equity | -63.6% | -61.0% | -75.2% | -45.8% | -35.44% |
| Total Debt | $1.07M | $755.00K | $436.00K | $110.00K | -91.96% |
No podcast episodes available.
PRAX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
